癌症研究
免疫疗法
免疫检查点
免疫系统
癌症免疫疗法
纳米医学
癌症
乳腺癌
医学
癌细胞
上睑下垂
药品
DNA折纸
细胞
靶向给药
封锁
细胞毒性
靶向治疗
药物输送
T细胞
背向效应
免疫原性细胞死亡
作者
Xiaqing Gong,Yuan Han,Ying Fang,Mingming Song
摘要
The clinical response to immunotherapy in triple-negative breast cancer (TNBC) is often limited by the immunosuppressive microenvironment, immune cell exhaustion, and multidrug resistance. Through a high-throughput screen of 2,500 FDA-approved drugs using a three-dimensional tumor organoid platform, we identified thonzonium bromide (THO) as an inducer of gasdermin D (GSDMD)-mediated pyroptosis, which results in the release of damage-associated molecular patterns (DAMPs) to activate antitumor immunity. To achieve targeted delivery, we designed a core-shell-structured biomimetic nanoparticle (THO/AMT-si NP) consisting of a core formed by tetrahedral DNA (TDN NPs) constructed using DNA origami technology, which is loaded with THO and P-gp siRNA, and an outer layer coated with a programmatically designed hybrid membrane (AREP). These findings indicate that THO/AMT-Si NPs can effectively target TNBC tumors, convert "cold" tumors into "hot" tumors by inducing pyroptosis in cancer cells, reverse immune cell exhaustion, and simultaneously overcome cancer cell multidrug resistance, thereby achieving synergistic inhibition of tumor growth and metastasis. In summary, this biomimetic nanomedicine enhances immunotherapy for TNBC by combining synergistic cascade targeting, immune checkpoint blockade, and thermosis-mediated immune activation.
科研通智能强力驱动
Strongly Powered by AbleSci AI